A2 Milk share price on watch following US FDA approval

A2 Milk shares could avoid the selloff on Thursday after some big news…

| More on:
A woman standing on the street looks through binoculars.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • A2 Milk shares will be one to watch closely this morning
  • That's because the company will soon be able to sell its infant formula in the US market
  • This morning the company revealed that the US FDA has approved its products

The A2 Milk Company Ltd (ASX: A2M) share price will be one to watch on Thursday.

That's because this morning the infant formula company made a very positive announcement relating to its US operations.

Why is the A2 Milk share price on watch?

The A2 Milk share price could defy the market selloff today after the company announced that it will soon be selling its infant formula in the massive US market.

According to the release, the United States Food and Drug Administration (FDA) has exercised its discretion to allow A2 Milk to import infant milk formula products into the United States.

A2 Milk applied to the FDA on 26 May but had its application deferred in August. Since then, the company continued to engage with the FDA to meet its requirements and to reconsider A2 Milk's application.

It has now done enough to convince the FDA to approve its application and has been given the thumbs up to import, sell, and distribute a2 Platinum infant formula products (Stages 1 and 2) from New Zealand into the US through to 6 January 2023. The company is also able to supply Stage 3 toddler products, which does not require enforcement discretion.

What's different?

The release notes that the product that will be supplied to the United States has the same formulation as a2 Platinum but has different scoops, mixing instructions, and labelling requirements to meet the FDA requirements. This product is not currently available in inventory and needs to be manufactured as soon as possible.

A2 Milk previously indicated to the FDA that if approval was obtained by 30 September 2022, it had the capacity through Synlait Milk Limited (ASX: SM1) to manufacture 9 million cans of a2 Platinum (equivalent to 211 million 8oz bottles) by 30 June 2023 if required during the supply shortage period, subject to customer demand.

However, management highlights that while the United States is a significant opportunity, it is difficult to predict the infant formula sales potential as it is a highly competitive market to enter.

Accordingly, the company believes sales will be significantly below indicated manufacturing capacity and is provisionally forecasting sales of 1 million cans to the United States during the second half of FY 2023.

Furthermore, management expects gross margins to be lower than average, distribution costs to be higher due to potential air freight and rework costs, and incremental marketing and trade investment to enter the category. This makes its earnings impact unclear at this stage.

Management commentary

A2 Milk Company's managing director and CEO, David Bortolussi, said:

We are pleased to be able to assist parents and caregivers in the US by providing access to significant volumes of high quality, a2 Platinum infant and toddler milk formula manufactured in New Zealand during this challenging period. Our a2 Platinum product meets the FDA's food safety and nutritional requirements and is made with a2 Milk, which has digestive and other potential health benefits that have underpinned the success of our brand in other markets.

a2MC is well positioned to support this initiative being one of the leading premium international infant milk formula brands with annual sales exceeding 30 million cans. We have scalable production capacity in New Zealand with Synlait plus existing a2MC US sales, marketing and supply chain capability that can be leveraged.

We are increasing our supply to respond to this situation, while importantly ensuring that we continue to meet the needs of our other IMF consumers and trade partners in China and other markets. If the US requires further support over an extended period, we have the proven ability to scale up significantly.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Consumer Staples & Discretionary Shares

Happy friends at a party enjoying pizza, symbolising the Domino's share price.
Broker Notes

Buy, hold, or sell Domino's Pizza shares after shock CEO exit? Here's what the experts say

The Domino's share price has been recovering after losing a quarter of its value last Wednesday.

Read more »

Photo of a happy couple with their car and car keys.
Consumer Staples & Discretionary Shares

What are Macquarie's top ASX All Ords picks in the automotive sector?

Aussie investors are becoming increasingly interested in auto stocks.

Read more »

basket of grocery items with smart phone ordering system
Consumer Staples & Discretionary Shares

Here's how Aldi plans to disrupt Coles and Woolworths with online shopping

Here’s Aldi’s latest move to try to win market share.

Read more »

Two male professional analysts discuss share price movements shown on the computer screen in front of them, with one pointing to a screen
Consumer Staples & Discretionary Shares

Broker tips 40-52% upside for these ASX consumer staples shares

This broker is tipping a big year ahead for these ASX shares.

Read more »

Happy couple doing online shopping.
Consumer Staples & Discretionary Shares

Consumer dicretionary picks: what's Macquarie's price targets for Nick Scali and Harvey Norman shares?

This broker has a clear favourite.

Read more »

Woman presenting financial report on large screen in conference room.
Consumer Staples & Discretionary Shares

Why this consumer share is up 10% on earnings guidance

This company’s shareholders have seen their holdings gain 46% in a year.

Read more »

A man and a woman line up to race through a supermarket,.
Consumer Staples & Discretionary Shares

Supermarket battle: Does Macquarie see more upside for Woolworths or Coles shares?

Which stock should investors put in their shopping basket?

Read more »

Happy couple doing online shopping.
Consumer Staples & Discretionary Shares

Furniture battle: Does Macquarie prefer Nick Scali or Temple & Webster shares?

Let's see which one the broker is recommending to clients.

Read more »